Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).

Jae Hee Cheon,Hyun-Soo Kim,Dong Soo Han,Sung Kook Kim,Sung Jae Shin,Joo Sung Kim,Byong Duk Ye,Geun Am Song, YoungJa Lee,Youngdoe Kim,Yoosun Lee,Won Ho Kim

Gut and liver（2022）

引用 1|浏览12

暂无评分

摘要

This study provided evidence that infliximab 5 mg/kg induction and maintenance therapies are efficacious and well-tolerated in patients with moderate-to-severe active intestinal BD. (ClinicalTrials.gov identifier: NCT02505568).

查看译文

关键词

Behcet syndrome,Clinical efficacy,Infliximab,Intestinal diseases,Tumor necrosis factor-alpha

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要